About
Epigenovo AB is a Swedish start-up company developing products and services to decode epigenetic regulation from clinical FFPE samples and empower researchers to transform mechanistic insight from retrospective research into actionable insights for biomarker discovery and patient stratification.
Our Story
Built on years of academic research in cancer genomics and epigenetics and driven by a desire to harness the potential of FFPE samples, Epigenovo presents the first high-sensitivity epigenetic assays for FFPE samples compatible with both bulk and single cell workflows. Our proprietary technology enables high-throughput, high-sensitivity chromatin accessibility profiling in long-term archived FFPE samples. It supports retrospective and spatial epigenetic studies, advancing insights into tumor relapse, metastasis and precision medicine.
Why Epigenetics
Epigenetic research explores how genes are turned on or off without the DNA itself being changed. It investigates how epigenetic marks control the cell’s use of DNA and how these marks shift over time, a process that can contribute to diseases.
The reversible nature of epigenetics is key because it allows for therapies that can modify disease‑related gene activity. By uncovering these switches, we learn how they affect health and illness.
So, if you can analyze clinical FFPE samples, you can uncover disease‑linked epigenetic changes captured at key moments such as diagnosis, treatment response, relapse and metastasis and discover biomarkers for diagnosis and drug development.
GenomWeb: Epigenovo Developing Single-Cell Chromatin Accessibility Assay for FFPE Samples
Read about our groundbreaking technology and vision for transforming epigenetic research in this exclusive interview with GenomeWeb.
Why FFPE Samples
Formalin fixed paraffin embedded (FFPE) samples, being the gold standard for archiving clinical tissue, represent the most abundant clinical material globally. Yet it remains largely inaccessible to epigenetic profiling due to high degree of DNA damage, leaving a vast archive of clinical insights untapped.
Our Approach
We are developing a tool-box of Research Use Only (RUO) products for extracting high-quality nuclei from minute FFPE material and for chromatin accessibility and histone modification studies at bulk and single cell level. This enables researchers to investigate rare diseases and cancer development by learning from clinical samples stored in biobanks.
Nuclei isolation
Across diverse FFPE sample formats
DNA library prep
Optimized for degraded material
FFPE-ATAC
Bulk chromatin accessibility profiling
scFFPE-ATAC
High throughput single-cell resolution
FACT-seq
Histone modification mapping